David N Louis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6904320/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	7.7	12,144
2	The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 2007, 114, 97-109.	7.7	9,898
3	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	1.2	4,534
4	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 2014, 344, 1396-1401.	12.6	3,648
5	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	28.9	1,408
6	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature, 2016, 539, 309-313.	27.8	875
7	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
8	Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells. Cell, 2014, 157, 580-594.	28.9	751
9	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science, 2017, 355, .	12.6	743
10	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV― Acta Neuropathologica, 2018, 136, 805-810.	7.7	599
11	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. Brain Pathology, 1993, 3, 19-26.	4.1	597
12	MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 97-117.	22.4	566
13	<pre><scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435</pre>	4.1	499
14	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461
15	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	21.4	408
16	clMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the clMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
17	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
18	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine, 1999, 5, 881-887.	30.7	309

#	Article	IF	CITATIONS
19	Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. Journal of Neuropathology and Experimental Neurology, 1995, 54, 91-95.	1.7	306
20	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
21	clMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	7.7	281
22	The retinoblastoma gene is involved in malignant progression of astrocytomas. Annals of Neurology, 1994, 36, 714-721.	5.3	211
23	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
24	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	9.4	207
25	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	6.3	182
26	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathologica, 2019, 137, 683-687.	7.7	170
27	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	4.1	168
28	Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse. Neurosurgery, 2000, 47, 623-632.	1.1	165
29	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	7.7	145
30	Focus on central nervous system neoplasia. Cancer Cell, 2002, 1, 125-128.	16.8	130
31	The role of neuropathology in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 531-549.	2.9	120
32	Announcing clMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
33	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
34	Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathologica, 1993, 86, 81-85.	7.7	93
35	Implementing the DICOM Standard for Digital Pathology. Journal of Pathology Informatics, 2018, 9, 37.	1.7	93
36	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/190 Loss, Clinical Cancer Research, 2009, 15, 6430-6437.	7.0	88

#	Article	IF	CITATIONS
37	Use of MIB-1 (Ki-67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 857-865.	1.7	86
38	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. Journal of Neuropathology and Experimental Neurology, 2016, 75, 4-18.	1.7	81
39	Computational Pathology: An Emerging Definition. Archives of Pathology and Laboratory Medicine, 2014, 138, 1133-1138.	2.5	78
40	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. Journal of Infectious Diseases, 2020, 222, 1955-1959.	4.0	72
41	Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncology, 2015, 1, 662.	7.1	68
42	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT 27, 851-852.	/Overlock 4.1	10 Tf 50 5 63
43	The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Current Opinion in Neurology, 2017, 30, 643-649.	3.6	62
44	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nature Communications, 2018, 9, 810.	12.8	56
45	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Modern Pathology, 2015, 28, 596-606.	5.5	55
46	Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathologica, 1998, 95, 287-290.	7.7	54
47	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro-Oncology, 2017, 19, 1640-1650.	1.2	54
48	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncology, 2015, 4, 287-294.	3.0	48
49	Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Molecular Diagnostics, 2006, 8, 268-276.	2.8	43
50	The next step in brain tumor classification: "Let us now praise famous menâ€â€¦ or molecules?. Acta Neuropathologica, 2012, 124, 761-762.	7.7	35
51	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). Journal of Neuro-Oncology, 2016, 130, 31-42.	2.9	35
52	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-Oncology, 2017, 19, 1380-1390.	1.2	35
53	Evidence for Subarachnoid Spread in the Development of Multiple Meningiomas. Brain Pathology, 1995, 5, 11-14.	4.1	33
54	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. Seminars in Neurology, 2018, 38, 019-023.	1.4	30

#	Article	IF	CITATIONS
55	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro-Oncology, 2019, 21, 596-605.	1.2	25
56	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. Archives of Pathology and Laboratory Medicine, 2020, 144, 196-206.	2.5	21
57	Multicolumn Infusion of Gene Therapy Cells into Human Brain Tumors: Technical Report. Neurosurgery, 2000, 46, 663-669.	1.1	19
58	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro-Oncology, 2016, 19, now181.	1.2	17
59	Glioblastoma multiforme in four siblings: A cytogenetic and molecular genetic study. Journal of Neuro-Oncology, 1995, 24, 251-258.	2.9	15
60	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare. Acta Neuropathologica, 2017, 134, 517-520.	7.7	15
61	The 2013 symposium on pathology data integration and clinical decision support and the current state of field. Journal of Pathology Informatics, 2014, 5, 2.	1.7	14
62	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
63	Angioleiomyoma of the falx. Journal of Radiology Case Reports, 2016, 10, 8-15.	0.4	11
64	Clear cell pleomorphic xanthoastrocytoma: case report. Acta Neuropathologica, 2001, 102, 404-408.	7.7	10
65	An Ultra-High Speed Whole Slide Image Viewing System. Analytical Cellular Pathology, 2012, 35, 65-73.	1.4	9
66	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. Journal of Clinical Neuroscience, 2016, 31, 99-105.	1.5	8
67	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma Journal of Clinical Oncology, 2013, 31, 2029-2029.	1.6	7
68	Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. Somatic Cell and Molecular Genetics, 1997, 23, 221-223.	0.7	5
69	The flowering of pathology as a medical discipline in Boston, 1892-c.1950: W.T. Councilman, FB Mallory, JH Wright, SB Wolbach and their descendants. Modern Pathology, 2016, 29, 944-961.	5.5	4
70	Case 38-2016. New England Journal of Medicine, 2016, 375, 2381-2389.	27.0	3
71	Characterization of applicants for residency training in pathology: Does diversity exist?. Annals of Diagnostic Pathology, 2019, 40, 23-25.	1.3	3
72	The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. Journal of Neuropathology and Experimental Neurology, 2017, 76, 189-194.	1.7	2

#	Article	IF	CITATIONS
73	A feast of reviews about brain and pituitary tumor pathology. Brain Tumor Pathology, 2018, 35, 49-50.	1.7	2
74	A half century of change in diagnostic neuropathology: from the giants of yore to current brain tumor classification. Human Pathology, 2020, 95, 161-168.	2.0	2
75	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. Neuro-Oncology, 2018, 20, vi237-vi238.	1.2	1
76	Atretic cephalocele: Report of an infrequent dermatopathologic finding. Journal of Cutaneous Pathology, 2021, 48, 1439-1441.	1.3	1
77	PATH-32. BRAIN TUMOR CLASSIFICATION UPDATES FROM cIMPACT-NOW, THE CONSORTIUM TO INFORM MOLECULAR AND PRACTICAL APPROACHES TO CNS TUMOR CLASSIFICATION. Neuro-Oncology, 2018, 20, vi165-vi165.	1.2	0
78	Roses and rosettes—the two sides of James Homer Wright. Baylor University Medical Center Proceedings, 2020, 33, 286-292.	0.5	0
79	Update on Clioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
80	Paul Kleihues (1936–2022), neuropathology innovator and entrepreneur. Brain Pathology, 2022, 32, e13073.	4.1	0